Abraham Abuchowski, recognized for his ability to blend scientific knowledge with business acumen, is a pioneer who creates drugs to treat childhood diseases. In 1983, Abuchowski cofounded Enzon, Inc., the first New Jersey biotechnology company to receive FDA approval for a biopharmaceutical. That product was Adagen, a groundbreaking treatment for “bubble boy syndrome.” Enzon also developed Oncaspar, used to treat children with acute lymphoblastic leukemia. As chair and CEO, Abuchowski helped Enzon mature into a fully integrated pharmaceutical company. In 1996, he left Enzon to start New Paradigm Consulting, Inc., which helps entrepreneurs turn their ideas into startup businesses. Founder and first chair of the Biotechnology Council of New Jersey, he co-chaired the New Jersey Legislative Task Force on Biotechnology. Rutgers–Camden placed him among its top 50 graduates at its 50th anniversary in 2000. In 2002, Abuchowski founded Prolong Pharmaceuticals, a company committed to developing novel biopharmaceuticals using his pioneering drug delivery technology, PEGylation.